scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1033998707 |
P356 | DOI | 10.1186/1756-0500-6-82 |
P932 | PMC publication ID | 3606324 |
P698 | PubMed publication ID | 23497453 |
P5875 | ResearchGate publication ID | 236051890 |
P50 | author | Nigel Rawson | Q67562857 |
P2093 | author name string | Jorge A Ross Terres | |
P2860 | cites work | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
Changes in glitazone use among office-based physicians in the U.S., 2003-2009. | Q33751542 | ||
Database size and power to detect safety signals in pharmacovigilance | Q36984256 | ||
Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | Q37240896 | ||
Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone | Q37572625 | ||
Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. | Q41807349 | ||
Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. | Q43703608 | ||
New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm | Q46471450 | ||
P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | (RS)-rosiglitazone | Q424771 |
Canada | Q16 | ||
P304 | page(s) | 82 | |
P577 | publication date | 2013-03-05 | |
P1433 | published in | BMC Research Notes | Q15762797 |
P1476 | title | Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010 | |
P478 | volume | 6 |
Q43636050 | Fucosylated chondroitin sulfate from Acaudina molpadioides improves hyperglycemia via activation of PKB/GLUT4 signaling in skeletal muscle of insulin resistant mice |
Q38644070 | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies. |
Q35792497 | Rosiglitazone use and associated adverse event rates in Canada: an updated analysis |
Search more.